Capricor Therapeutics Q1 net loss widens as expenses rise

Capricor Therapeutics

12/05/2026 21:25

Overview

US biotechnology firm's Q1 2026 saw no revenue and net loss widened year-over-year

Company's lead therapy Deramiocel under FDA review with PDUFA target date August 2026

Cash position expected to fund operations into Q4 2027, excluding potential product sales

Outlook

Company expects FDA decision on Deramiocel BLA by August 22, 2026

Capricor expects cash balance to support operations into Q4 2027

Company preparing for potential Deramiocel launch; manufacturing expansion and stockpiling underway

Result Drivers

OPERATING EXPENSES - Higher research and development and administrative costs contributed to increased net loss in Q1

COMMERCIAL PREPARATIONS - Company expanded manufacturing capacity and prepared for potential Deramiocel launch, including facility expansion and hiring a Chief Commercial Officer

REGULATORY AND LEGAL ACTIVITIES - Ongoing FDA review of Deramiocel and legal action to address distribution agreement impacted operational focus

Company press release: ID:nGNX83jx95

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.59


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Capricor Therapeutics Inc is $54.00, about 69.3% above its May 11 closing price of $31.90

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)